Website is for EU physicians only*
BRILIQUE™ Efficacy and Safety
Ticagrelor Mechanism of Action
European Society of Cardiology ACS Guidelines
BRILIQUE™, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
*For physicians in 27 member states of the EU, Norway, Iceland and Liechtenstein.